Anshika Jain
Modern medicine is undergoing a fundamental transition from treating diseases after symptoms become visible to identifying potential health risks before they develop into serious medical conditions. Traditional preventive medicine relies on clinical examinations, family history, blood tests, imaging, and established risk factors such as age, blood pressure, cholesterol, and body mass index. Although these methods remain essential, they often provide only periodic snapshots of an individual’s health. They may not fully capture the behavioural changes that emerge gradually between medical appointments.
Digital phenotyping introduces a different approach by examining patterns in everyday human behaviour through smartphones, wearable devices, connected sensors, and digital health platforms. It converts selected aspects of daily activity, mobility, sleep, communication, and physiological functioning into measurable data that researchers can analyse for potential health insights. When integrated with preventive medicine, this approach could help clinicians identify subtle changes that precede the development or worsening of certain health conditions.
The central question is whether behaviour can function as a biomarker. In conventional medicine, biomarkers include measurable biological characteristics such as blood glucose, inflammatory proteins, hormone levels, and genetic variations. Behavioural patterns are different because they are influenced by numerous biological, psychological, environmental, and social factors. Nevertheless, when measured consistently and interpreted within an appropriate clinical context, changes in behaviour may provide valuable indicators of changing health status. The convergence of digital phenotyping and preventive medicine therefore represents an emerging opportunity to make healthcare more continuous, personalised, and proactive.
Understanding Digital Phenotyping and Behavioural Biomarkers
Digital phenotyping refers to the measurement and analysis of human characteristics through data generated by personal digital devices. These data may include movement patterns, physical activity, sleep duration, smartphone interaction, voice characteristics, typing behaviour, location patterns, and selected physiological measurements. Researchers use statistical methods and artificial intelligence to identify meaningful relationships between these signals and health outcomes.
The concept extends beyond simply counting steps or recording sleeping hours. Its distinctive value lies in examining how an individual’s behaviour changes over time. For example, a reduction in daily movement may be more informative when compared with that person’s established activity pattern than when compared with a general population average. Similarly, changes in sleep regularity, social engagement, or mobility may provide clues about changes in physical functioning or psychological wellbeing.
A behavioural biomarker is a measurable behavioural feature that has demonstrated a reliable association with a particular biological process, clinical condition, or health outcome. The distinction between an ordinary behavioural observation and a validated biomarker is important. A smartphone recording fewer interactions does not automatically indicate depression, and reduced movement does not necessarily establish the presence of cardiovascular disease. Such observations become clinically meaningful only when research demonstrates their reliability, specificity, and usefulness for a defined medical purpose.
Digital phenotyping is therefore best understood as a developing measurement framework rather than a universal diagnostic technology. Research published in npj Digital Medicine has explored its potential for continuous health assessment, early diagnosis, and health management, while also identifying challenges involving clinical integration, data quality, and privacy. The technology’s future depends on establishing which behavioural signals are genuinely useful and under what circumstances they should influence healthcare decisions.
Why Preventive Medicine Needs Continuous Behavioural Monitoring
Preventive medicine traditionally evaluates risk through scheduled consultations and periodic testing. These assessments are valuable, but human behaviour and health can change substantially between visits. A person may gradually become less physically active, experience increasingly irregular sleep, or develop difficulties maintaining medication routines without immediately recognising the significance of these changes.
Continuous behavioural monitoring could help address this gap by providing a more detailed picture of everyday functioning. Instead of relying exclusively on a patient’s recollection of recent activity, a clinician may be able to review consented measurements collected over several weeks or months. This longitudinal perspective can help distinguish temporary fluctuations from persistent changes that may justify further investigation.
For example, an individual with an elevated risk of type 2 diabetes might use a wearable device to monitor physical activity and sleep consistency while participating in a preventive health programme. If their activity levels decline substantially over time, a healthcare professional could explore possible explanations, including work pressures, mobility difficulties, medication effects, or emerging health problems. The digital signal would not establish a diagnosis, but it could prompt a timely conversation and a more appropriate assessment.
This approach also has implications for personalised prevention. Two individuals with similar conventional risk scores may have very different daily routines, environmental constraints, and responses to lifestyle interventions. Behavioural data may help clinicians understand these differences and tailor preventive recommendations accordingly. However, the value of such information depends on whether the resulting interventions improve meaningful health outcomes rather than merely generating more data.
From Smartphones to Wearables: How Behaviour Becomes Measurable
Smartphones are important tools for digital phenotyping because they are widely used and contain sensors capable of recording aspects of everyday activity. Accelerometers and gyroscopes can estimate movement, while location services may help researchers study mobility patterns when users have provided appropriate consent. Interaction patterns can reveal changes in device use, and voice or speech features may offer additional information in carefully designed research settings.
Wearable devices extend these capabilities by collecting measurements closer to the body. Depending on the device, they may record heart rate, activity intensity, sleep-related estimates, and other physiological signals. Some systems combine these measurements with behavioural information to investigate relationships between daily routines and health indicators.
The analytical process typically involves collecting data, processing it into meaningful features, comparing patterns over time, and evaluating whether those patterns correspond to clinically relevant outcomes. Machine-learning models may identify combinations of changes that would be difficult to recognise through isolated observations. However, a model’s ability to identify statistical patterns does not automatically mean it can explain why those patterns occur or accurately predict disease in every population.
Data quality also varies according to device design, sensor accuracy, charging habits, operating systems, and user behaviour. A phone left at home may incorrectly suggest reduced mobility, while a wearable that is not worn during sleep may produce incomplete records. Reliable digital phenotyping therefore requires careful handling of missing information and an understanding of the circumstances in which data were collected.
Mental Health: One of the Most Promising Applications
Mental healthcare is among the most extensively discussed areas of digital phenotyping because many psychological changes affect everyday routines, communication, sleep, movement, and social interaction. Conventional mental health assessments often rely on clinical interviews, questionnaires, patient histories, and professional observation. These methods remain indispensable, but they may not capture every fluctuation in symptoms between consultations.
Digital phenotyping could supplement these assessments by helping clinicians understand changes in an individual’s usual behavioural patterns. For instance, a sustained reduction in mobility, altered sleep timing, or changes in communication patterns might be relevant when evaluating a person with a known mental health condition. Longitudinal measurements may also help researchers investigate whether certain behavioural changes precede symptom deterioration or relapse.
A 2025 review of smartphone-based digital phenotyping in mental health research examined sensor use, machine-learning pipelines, and behavioural features, including the potential of longitudinal measurements to support the analysis of symptom trajectories and relapse prediction. These findings illustrate the direction of research, not proof that smartphone data can independently diagnose mental health conditions.
The major challenge is that behavioural signals are rarely specific to one condition. Reduced social interaction may reflect depression, but it may also result from travel, examinations, work schedules, personal preferences, or limited internet access. An algorithm that interprets these patterns without contextual information could produce misleading conclusions.
Consequently, digital phenotyping should support clinical conversations rather than replace them. Patients must retain the ability to explain changes in their circumstances, challenge inaccurate interpretations, and decide whether particular forms of monitoring are appropriate for their care.
Cardiometabolic Prevention and the Measurement of Everyday Habits
The convergence of digital phenotyping and preventive medicine is also relevant to cardiometabolic conditions, including obesity, type 2 diabetes, hypertension, and cardiovascular disease. These conditions are influenced by multiple interacting factors, such as physical activity, sedentary behaviour, sleep, dietary patterns, medication adherence, genetics, and social circumstances.
Traditional clinical tests can identify important risk factors, but they do not always explain the daily routines contributing to those risks. Digital tools could help researchers and healthcare professionals examine how lifestyle patterns develop and whether preventive interventions lead to sustained behavioural changes.
A scoping review published in 2025 examined digital phenotyping approaches for cardiometabolic risk prevention and management. The review included 73 studies and considered behaviours such as physical activity, sedentary time, sleep, dietary habits, and medication adherence, alongside a range of health-related risk factors. It identified opportunities for personalised risk assessment while highlighting the need for further development and evaluation.
Consider a person enrolled in a programme to reduce their risk of cardiovascular disease. A wearable could help track movement and sleep patterns, while a connected application might support medication reminders and record self-reported dietary habits. If activity declines and medication routines become inconsistent, the system could encourage a follow-up with the care team. A clinician could then determine whether the patient needs additional support, a treatment review, or a change in the prevention plan.
Such an approach would be most effective when behavioural measurements are combined with established clinical indicators. Wearable data cannot replace blood pressure measurements, cholesterol testing, glucose assessments, or other clinically indicated examinations. Instead, it may provide additional context that helps healthcare professionals interpret risk and support sustainable behaviour change.
Artificial Intelligence and the Development of Personalised Risk Models
Artificial intelligence provides the analytical infrastructure for extracting patterns from large and complex behavioural datasets. Conventional assessments often depend on predefined thresholds and population-level risk estimates. AI-assisted systems may additionally examine combinations of signals, changes over time, and relationships between an individual’s established baseline and their current behaviour.
This creates the possibility of personalised risk modelling. Rather than treating a particular number of daily steps as equally meaningful for everyone, an algorithm could evaluate whether a person’s activity has changed significantly relative to their normal routine. It might also examine whether that change occurs alongside alterations in sleep, heart rate, or self-reported wellbeing.
However, personalised models must be distinguished from reliable clinical prediction. An algorithm may identify an association between a behavioural pattern and a health outcome without demonstrating that the pattern causes the outcome. It may also perform well in one research population but poorly in another because of differences in age, occupation, disability, culture, device ownership, or underlying disease prevalence.
Clinical deployment therefore requires rigorous validation, transparent reporting, and ongoing monitoring of model performance. Researchers must establish whether a system improves early identification, supports appropriate interventions, and produces better outcomes than existing approaches. Without this evidence, sophisticated algorithms risk creating alerts that increase anxiety and healthcare workload without providing meaningful benefits.
The Ethical Challenge: When Everyday Behaviour Becomes Health Data
Digital phenotyping creates a significant ethical challenge because information generated during ordinary activities can reveal sensitive aspects of an individual’s life. Movement patterns may suggest where someone spends time, while communication patterns and sleep behaviour may expose personal routines. When these signals are combined, they may permit inferences about psychological wellbeing, physical health, or social circumstances that users never intended to disclose.
Privacy must therefore be central to the design of behavioural monitoring systems. People should understand what information is being collected, why it is needed, how long it will be retained, who can access it, and whether it will be shared with third parties. Consent should be meaningful and understandable, with practical opportunities to withdraw from monitoring without inappropriate penalties.
Research published in npj Digital Medicine has emphasised the importance of transparency, informed consent, privacy protection, and accountability in digital phenotyping. These concerns are particularly important when systems collect data continuously or use machine learning to infer information that was not directly provided by the individual.
There is also a risk that behavioural scores could be misused by employers, insurers, educational institutions, or commercial platforms. If a system labels someone as having a high predicted health risk, that classification could influence decisions beyond the intended clinical setting. Strong safeguards are needed to prevent inappropriate secondary use, discrimination, and the creation of permanent risk profiles from uncertain predictions.
Ethical monitoring must preserve individual autonomy. People should not be forced to surrender extensive personal data to access routine healthcare, and the absence of smartphone or wearable data should never be interpreted as evidence of poor health behaviour.
Bias, Accessibility, and the Limits of Behavioural Interpretation
Digital phenotyping systems are not automatically objective simply because they use numerical measurements. Their outputs reflect the devices used, the populations studied, the assumptions embedded in algorithms, and the quality of the data collected.
A model developed using relatively healthy, digitally connected adults may perform poorly for older people, individuals with disabilities, people living in rural communities, or those who cannot afford compatible devices. Cultural differences can also affect the interpretation of movement, social interaction, sleep, and communication patterns. A routine that appears unusual to an algorithm may be entirely normal within a person’s circumstances.
Environmental conditions introduce further complications. A decline in outdoor movement may reflect extreme weather, unsafe neighbourhoods, caregiving responsibilities, or limited access to public spaces rather than an emerging medical problem. Treating these patterns as individual behavioural failures would ignore the wider determinants of health.
To reduce these risks, researchers should test digital phenotyping models across diverse populations and evaluate their performance for relevant demographic and clinical groups. Patients and healthcare professionals should participate in the design and evaluation process. Systems should also communicate uncertainty and allow clinical teams to question or disregard misleading outputs.
Preventive medicine must not become a system in which every deviation from an algorithmically defined norm is treated as a problem requiring correction. Human variation is expected, and healthy behaviour differs according to individual circumstances.
Integrating Digital Phenotyping into Clinical Practice
Successful integration requires more than installing a monitoring application or connecting a wearable to a hospital information system. Healthcare organisations need clear protocols for deciding which signals matter, who reviews alerts, how abnormal patterns are investigated, and how findings are documented.
Clinicians must also avoid excessive alert generation. If a monitoring system repeatedly flags minor changes that do not require intervention, healthcare professionals may experience alert fatigue and become less responsive to important signals. A practical system should distinguish between routine fluctuations, patterns that merit discussion, and situations that require more urgent assessment, using thresholds validated for the intended population and clinical purpose.
Interoperability is another requirement. Behavioural information should be incorporated into clinical workflows in a way that supports, rather than overwhelms, existing records and decision-making processes. Healthcare professionals need appropriate training to understand the limitations of sensor measurements, interpret algorithmic predictions, and explain results to patients.
The effectiveness of implementation should be evaluated through meaningful outcomes, including earlier appropriate intervention, improved management of risk factors, patient experience, and equitable access. The number of measurements collected or alerts generated is not sufficient evidence of success.
For healthcare systems with limited resources, including many settings in India, digital phenotyping may offer opportunities for remote monitoring and more continuous preventive support. Nevertheless, implementation must account for uneven internet connectivity, affordability, language accessibility, digital literacy, and the availability of trained healthcare professionals. Low-cost designs and non-digital alternatives will be important to prevent these technologies from widening existing health inequalities.
The Future of Behaviour as a Clinical Biomarker
The future of digital phenotyping will depend on whether researchers can move from detecting behavioural correlations to establishing clinically useful, validated measures. This requires longitudinal studies, reproducible analytical methods, representative research populations, and evidence that acting on digital signals improves health outcomes.
One promising direction is the combination of behavioural data with conventional clinical measurements, laboratory results, medical history, and environmental information. Such integration could provide a more complete view of health while reducing reliance on any single signal. Researchers may also develop models that explain how behavioural changes relate to individual risk trajectories, although the accuracy and practical value of these approaches must be established through rigorous evaluation.
Regulatory and ethical frameworks will need to evolve alongside technical capabilities. Digital health developers, clinicians, researchers, policymakers, and patients must share responsibility for defining appropriate uses, protecting sensitive information, and ensuring that predictive systems remain accountable. Guidance from the World Health Organization on AI ethics and governance in health emphasises the importance of human rights, transparency, accountability, and public benefit when these technologies are developed and deployed.
The ultimate goal should not be to monitor every human action. It should be to identify a limited set of reliable, relevant signals that help people and healthcare professionals make better decisions while preserving privacy and personal freedom.
Conclusion: From Behavioural Data to Preventive Insight
The convergence of digital phenotyping and preventive medicine offers a compelling opportunity to understand health as a changing process rather than a condition assessed only during occasional clinical visits. Smartphones, wearable devices, connected sensors, and artificial intelligence can reveal patterns in movement, sleep, communication, and daily routines that may complement conventional medical assessments.
Behaviour can become a useful biomarker when it is measured reliably, interpreted within context, and validated for a specific clinical purpose. It cannot be treated as a definitive indicator of disease simply because an algorithm identifies a statistical association. The distinction between a potentially informative signal and a clinically established biomarker must remain central to responsible adoption.
As research advances, digital phenotyping may support earlier risk identification, more personalised prevention, and better-informed conversations between patients and healthcare professionals. Achieving these benefits will require strong evidence, equitable access, data protection, and meaningful human oversight.
The future of preventive medicine will not depend on collecting the largest possible volume of behavioural data. It will depend on understanding which patterns genuinely matter, when they justify action, and how they can improve health without compromising the dignity and autonomy of the people they are intended to serve.